Three phases of clinical trials have shown that a new drug named Ocrelizumab is able to effectively treat patients with primary progressive multiple sclerosis

BANGALORE, INDIA, November 11, 2015 /EINPresswire.com/ -- A new drug that underwent clinical trials in the UK has shown dramatic signs of slowing the progression of multiple sclerosis. The results of the clinical trials were announced a few days ago.

This new drug that underwent clinical trials recently in the first ever treatment for people with a certain form of the multiple sclerosis and promise to offer a far more effective alternative to existing drugs.

A huge clinical trial was undertaken for the drug and was tested in hospitals across the UK helps to provide hope for more than 2.3 million people worldwide suffering with multiple sclerosis.

The drug, called Ocrelizumab has been claimed to have shown positive results in late-stage clinical trials to treat multiple sclerosis. 1,656 patients with recurring multiple sclerosis were treated with the new drug in two of the three studies.


During the third phase of the clinical trial, about 732 patients suffering from the less common but extremely serious primary progressive multiple sclerosis were treated with the new drug. Along with the decrease in progression rate of the multiple sclerosis disease, during the clinical trials, researchers found that the new treatment was far more effective than the currently available Rebif.

However, 10% of patients suffered serious side effects by using the new drug against the disease despite having multiple benefits.

Researchers say that the success of the clinical trials would prove successful in delivering promising results for at least more than 400,000 people suffering from multiple sclerosis in the US only. In the UK, more than 50 people in Britain, usually in their 20s or 30s, are diagnosed each week with this most common disabling neurological condition.

Multiple sclerosis gets triggered when environmental conditions come in favor of the disease as some people are genetically predisposed to the disease. While the disease does not pose any threat to life, people suffering from the disease have a major impact on the life of people and can even lead to suicides.
Loss of mobility, sight problems, tiredness and excruciating pain is caused by the condition that affects twice as many women as men. With many people left relying on wheelchairs, the disease either becomes progressively worse with age - or strikes in brutal, periodic relapses.

The experimental drug was more effective in lowering the progression of the disabling disease than was a placebo in the third phase of the clinical trial, which had a total of 732 patients suffering from primary progressive multiple sclerosis.

For more market research reports on Clinical Trial Market visit
https://literated.com/industry/Clinical-Trials

About Literated.com
Literated.com is a one stop market research and e-commerce platform catering to the needs of businesses and knowledge workers who are dependent on market research information for their work.
Visit https://literated.com for more info.

Sachidanand Bhat
Literated.com
8971520970
email us here